Breast Cancer Clinical Trial
— CHOICEOfficial title:
Diet Composition, Weight Control, and Breast Carcinogenesis
Verified date | February 2013 |
Source | Colorado State University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
In the United States, overweight (BMI > 25 but < 30 Kg/m2) and obesity (BMI > 30Kg/m2) are
increasing at epidemic rates. A significant association exists between being overweight or
obese and breast cancer recurrence and survival. However, evidence continues to accumulate
indicating that achieving or maintaining a healthy weight for height (Body Mass Index, BMI,
18.5-25Kg/m2) is associated with a reduced risk for breast cancer and with a decrease in
breast cancer associated mortality. Despite this, there is a lack of randomized controlled
trials exploring this association and how the process of fat loss or being successful in
actually reaching a healthy weight for height differentially affects biomarkers for cancer
recurrence.
Many dietary approaches for weight loss are currently available to the public, and each
purports to offer advantages. However, there is little scientific evidence to indicate how
these dietary approaches, some of which vary markedly in the foods that they limit or
exclude, affect biomarkers for breast cancer risk. In particular, it is not know whether the
critical factor in relation to weight and breast cancer is simply weight loss (negative
energy balance), irrespective of the manner in which it is achieved, or if certain dietary
approaches affect breast cancer risk biomarkers more favorably than others. Published data
from our laboratory suggest that dietary pattern does matter, and therefore the goal of this
study is to investigate the effects of two popular weight loss dietary approaches that
differ in the extent to which they limit carbohydrate or fat consumption (with effects on
dietary glycemic load) compared to a usual care group on prognostic markers for cancer
recurrence in postmenopausal breast cancer survivors. The investigators hypothesize that in
addition to the anticipated effects of fat loss on circulating levels of bioavailable sex
steroid hormones, that the effects of excess fat on breast cancer prognosis can be
attributed to three interrelated metabolic processes that affect cancer progression: altered
glucose metabolism, chronic inflammation and excessive cellular oxidation.
Status | Completed |
Enrollment | 259 |
Est. completion date | June 2012 |
Est. primary completion date | January 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: - Female breast cancer survivors - Staged, resected breast cancer (> 4-months post radiation treatment, chemotherapy or surgery) - Post-menopausal (no menses for > 6 months) - No evidence of metastatic breast disease - Willing to follow the diet plan prescribed - Willing to follow the guidelines for alcohol consumption (no more than 1 standard alcoholic drink per day where one serving is defined as 12oz beer, 5 oz wine OR 1 oz hard liquor) - Willing to maintain or increase current physical activity level - Willing to wear a pedometer and keep a daily record of steps - Willing to wear heart rate/ accelerometer device (Actiheart) continuously (24/7) for one week at the start and end of the study - Willing to wear a body or swim suit and cap for body composition tests - Willing to record food intake daily - Willing to come to RMCC Rose for 11 individual and 5 group sessions over a 6 month period - Willing to provide urine and fasting blood samples at 7 visits during the study - Willing to make the commitment it takes to lose weight for the study - Must have a Body Mass Index between 25Kg/m2 to 35Kg/m2. Exclusion Criteria: - Anticipates having surgery during the next 6 months - Follows a special diet, e.g. gluten free, casein free, dairy free, vegetarian or other - Lost 4 or more pounds during the previous month - Taking weight loss medications during the study - Being treated by a physician for diabetes - Has an eating disorder - Has digestive problems such as IBS (Irritable Bowel Syndrome), Crohn's or other - Has had surgery involving constriction or removal of any portion of the gastrointestinal tract (gastric bypass, lap-band, bowel resection, colostomy etc. - Diagnosed with hepatitis B, hepatitis C or HIV - Has electronic devices implanted in their body (pacemaker, vagus nerve stimulator) - Must not use any tobacco products |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United States | Rocky Mountain Cancer Center | Denver | Colorado |
Lead Sponsor | Collaborator |
---|---|
Colorado State University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Inflammation Markers | C-reactive protein, IL-6, TNF-alpha | Baseline and montlhly for 6 months | No |
Secondary | Body Fat Percentage (%) | % Body fat, % lean muscle mass, Resting Metabolic Rate (RMR) using the BODPOD (Volumetric weighing; Life Measurement, Inc.) and Tanita Bioelectrical Impedence (BI) | Baseline and monthly for 6 months | No |
Secondary | Waist Hip Ratio | Calculated by measuring and dividing waist and hip circumferences | Baseline and monthly for 6 months | No |
Secondary | Weight | Using 1) BODPOD (Life Measurement, Inc.) and 2) Tanita Bioelectrical Impedence Scale | Baseline and monthly for 6 months | No |
Secondary | Bioavailable sex steroid hormones | estradiol, estrone, sex hormone binding globulin (SHBG) | Baseline and monthly for 6 months | No |
Secondary | Glucose metabolism | glucose, insulin, IGF-1, IGFBP-3, glycated proteins (HbA1c) | Baseline and monthly for 6 months | No |
Secondary | Cellular oxidation | 8-hydroxy-2-deoxyguanosine, DNA damage sensitivity and repair and 8-isoprostane-F-2-alpha | Baseline and monthly for 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |